Structuring cell-cycle biology  by Levine, Kristi & Cross, Frederick R
KRIsTI LEVINE AND FREDERICK R CROSS MINIREVIEW
Structuring cell-cycle biology
The recent determination of the crystal structures of both cyclin A
and the cyclin A-CDK2 complex provides new insight into the
cyclin-dependent activation of cyclin-dependent protein kinases.
Structure 15 November 1995, 3:1131-1134
The recent determination of the structures of cyclin A and
the complex formed between cyclin and cyclin-depen-
dent kinase 2 (CDK2) is likely to be critical for
understanding the cell-cycle control that is carried out by
the diverse class of cyclin-CDK enzymes [1,2]. In order to
understand the biological significance of these structures,
and the questions still remaining that become much more
pointed with the structures in hand, we review, below, the
cell biology of the cell cycle, cyclins, and CDKs.
The eukaryotic cell cycle is a process of cell growth,
DNA replication, mitosis, and cytokinesis. The process is
typically divided into four phases; DNA replication or
synthesis (S phase) and mitosis (M phase), separated by
two gap phases, G1 and G2 [3]. Progression through the
cell cycle is driven by the sequential activation and
inactivation of the CDKs. The kinase activity of these
CDKs is dependent upon their physical association with
regulatory subunits known as cyclins. Although cyclins
were originally defined as proteins whose levels oscillate
during the cell cycle, they are now functionally defined
as members of a family of structurally related proteins
that bind and activate CDKs. In addition to activating the
CDK with which they associate, cyclins are thought to
contain regions that target the phosphorylation of
specific substrates [4]. The phased activation of various
cyclin-CDK complexes is probably important in trigger-
ing key cell-cycle transitions [5]. All eukaryotic cells
contain multiple distinct cyclins, in addition to (especially
in mammalian cells) multiple CDKs [6].
Cyclins are often subtyped according to sequence
similarities, as it is the case for the A-type and B-type
cyclins, named in reference to their respective similarities
with two of the first cyclins identified, clam cyclin A and
B [3]. Alternatively, cyclins may be subtyped according to
their function, or to the cell-cycle stage in which they
are thought to act, as in the case of the budding yeast
CLN cyclins. The family of cyclin-dependent kinases, or
CDKs, began with the identification of CDC28, one of
a number of budding yeast genes that, when mutant, was
found to produce an arrest at a particular point in the
cell-division cycle [3]. The fission yeast homolog of
CDC28 is known as cdc2+, and the first human cyclin-
dependent kinase to be identified, known also as CDC2
(or CDK1), was cloned by its ability to complement a
fission yeast cdc2 temperature-sensitive mutation [3]. The
additional cyclin-dependent kinase homologs found in
mammalian cells have been named in order of their
identification, from CDK2 to CDK7. For consistency
with the published papers under review [1,2], all protein
products discussed here are indicated in capital letters.
Gene names follow conventional usage.
Different cyclins vary in their ability to activate specific
CDK catalytic subunits. In budding yeast, the CLN
cyclins act early in the cell cycle to promote the
'START' transition [7,8], whereas B-type cyclins (CLBs)
promote S phase and mitosis [9-13]. These cyclins all
interact with the cyclin-dependent kinase CDC28. In
mammalian cells, D-type cyclins (when interacting with
CDK4 and CDK6) may respond to growth factors,
cyclins E and A bound to CDK2 may promote S phase,
and cyclin A and B-type cyclins bound to CDC2
promote mitosis [6].
At least in the case of the B-type cyclins that promote
mitosis, cyclin degradation is required before resetting of
the system can occur [11,14-16]. Entry into mitosis,
which is promoted by the active cyclin-CDK enzyme,
triggers cyclin degradation that probably results from the
direct activation of a cyclin-ubiquinating complex [17-20].
Cyclin specificity
In addition to activating the kinase, it has been suggested
that cyclins target the kinase complex to specific
substrates. Targeting may be the result of cyclin-induced
modulation of substrate specificity or subcellular localiza-
tion. Thus, the phased activation of different cyclin types,
and corresponding cyclin-CDK complexes, may be
responsible for the phosphorylation of distinct com-
ponents of the cell-cycle machinery, triggering different
key cell-cycle events.
In Saccharomyces cerevisiae, the 'START' transition (which
occurs in G1 and leads to bud emergence and gene
transcription, among other responses), S phase, and mito-
sis, are triggered by activation of first the CLN-CDC28
complex and then CLB-CDC28 complexes, in succes-
sion. At least some aspects of these cell-cycle transitions
require specific cyclins, and will not occur even when
inappropriate cyclins are strongly overexpressed [21-23].
Cyclin specificity has also been observed in higher
eukaryotes. For example, in Drosophila cyclin B is unable
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to functionally substitute for a deficiency of cyclin A
[24]. Overexpression of cyclin E or D1, but not B1, in
rat fibroblasts causes an acceleration in the transition from
G1 to S phase [25-27].
In a few cases, the specificity of cyclins for certain
substrates has been demonstrated biochemically. For
example, whereas A and B type cyclins when complexed
with CDC2 or CDK2 phosphorylate histone H1 with
comparable efficiencies, only the complexes with
cyclin A are able to stably bind to and phosphorylate
the Rb-related protein p107 [28]. Similarly, cyclin
A-CDK2, but not cyclin B-CDK2, is able to efficiently
phosphorylate p5 3 [29]. Additionally, whereas both
cyclin A-CDK2 and cyclin E-CDK2 complexes have the
ability to phosphorylate pRb, only cyclin A-CDK2 can
phosphorylate E2F effectively [30].
In addition to differentially modulating cyclin-CDK
substrate specificity, cyclins may promote the phosphory-
lation of specific substrates through their differential
localization of these cyclin-CDK complexes. For exam-
ple, cyclin A is preferentially localized to the nucleus,
whereas cyclin B1 is primarily cytoplasmic [31]. Addi-
tionally, human cyclins B1 and B2, cyclins that are active
during mitosis and that appear to have similar in vitro
substrate specificities, were found to have strikingly
different subcellular localizations, implicating them in
distinct mitotic roles [32].
CDK phosphorylation
Inhibitory phosphorylation
CDKs contain a highly conserved tyrosine residue (Tyrl5
in human CDC2 and CDK2). In many organisms,
including Schizosaccharomyces pombe, Xenop us, and
humans, inhibitory phosphorylation of this conserved
residue in CDC2 regulates the initiation of mitosis, and
a neighboring threonine residue (Thrl4) often also
contributes to this negative regulation [4].
Activating phosphorylation
Complete CDK activation requires the phosphorylation
of a threonine (Thrl60 in human CDK2 and Thrl61 in
CDC2) that is conserved amongst all CDKs [33,34].
Alanine, aspartic acid, or tyrosine substitutions at this
conserved residue in S. pombe cdc2 do not support cell
viability, and the alanine substitution eliminates CDC2
kinase activity. Interestingly, however, a glutamic-acid
substitution, possibly mimicking constitutive phosphory-
lation of the threonine residue, partially rescues a
temperature-sensitive cdc2 strain. The observation that
these mutant cells accumulate multiple septa and mitotic
spindles, indicative of a delayed transit through mitosis, is
consistent with the possibility that threonine dephos-
phorylation may be required for exit from mitosis [33].
Similarly, it was reported that inhibition of both type 1
and type 2A phosphatases by okadaic acid, preventing the
dephosphorylation of CDC2 Thrl61, allows cyclin
degradation, but prevents CDC2 kinase inactivation [35].
In a separate study, however, isolated human CDC2
monomers, phosphorylated at Thrl6l, obtained after
incubation of CDC2 with cyclin E, were found to
exhibit minimal kinase activity, indicating that threonine
phosphorylation alone cannot fully activate CDC2 [36].
Phosphorylated monomers of CDK2 also have no
measurable HI-kinase activity [37].
In addition to promoting the activation of cyclin-CDK
complexes, phosphorylation of this conserved threonine
residue has been suggested to affect the affinity of inter-
actions between cyclins and CDKs [37].
The CDK-activating kinase
An enzyme capable of phosphorylating the activating
conserved threonine residue of various CDKs has been
identified. The enzyme, known as the CDK-activating
kinase, or CAK, is itself a cyclin-CDK complex, consist-
ing of a complex of CDK7 and cyclin H [37-42].
Whereas CAK appears to phosphorylate only cyclin-
associated CDC2 in a strictly cyclin-dependent manner
[37-39], CAK phosphorylation of CDK2 is observed
even in the absence of cyclin [37,40,41].
The structure
The cyclin A-CDK2 structure described by Jeffrey et al.
[2] explains, in a striking manner, the requirement for
cyclin for activation of the CDK protein kinase catalytic
activity: cyclin binding drastically remodels CDK2 archi-
tecture [2,43], resulting in an active kinase configuration
at the catalytic site which is very similar to that of protein
kinase A (see the accompanying review by Taylor for a
full explanation). The structure of uncomplexed cyclin
A, determined by Brown et al. [1], indicates that, in
contrast to the striking conformational change in CDK2,
the cyclin provides a rigid framework that does not alter
much in structure upon binding to the kinase. The origi-
nal definition of cyclins was as periodic proteins in the
cell cycle [44]. Cyclin periodicity was found to be due to
the requirement for cyclin degradation and resynthesis to
allow cyclical activation of CDC2 [3,44]. Looking at the
structure, it is clear why cyclin abundance provides an
absolute regulation of CDK enzymic activity.
In addition, as was suspected [43], the 'T loop', which
occludes the suspected substrate-binding cleft of the
CDK2 monomer, is dramatically repositioned by cyclin
binding. A suspected occlusion of the substrate-binding
site that is still observed in the cyclin A-CDK2 structure is
speculated to be due to the lack of Thrl60 phosphoryla-
tion. It is speculated that phosphorylation of Thrl60 will
cause it to interact with a positively charged pocket, occu-
pied in the structure of Jeffrey et al. by the carboxyl group
of Glu162. Interestingly, this positively charged pocket
does not exist in monomeric CDK2; it is created by the
large conformational shifts that occur on cyclin binding.
Thus, it is abundantly clear why cyclin binding is required
for activation of the enzyme. But as we discussed
above, there is substantial genetic and some biochemical
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evidence to support the idea that cyclins contribute to the
substrate specificity of the associated CDK. Cyclins could
alter subcellular localization [31,32]; they could bind to
the substrate independently of the CDK (as in the case of
p107-cyclin A interaction [28] or the Rb-cyclin D1
interaction [45]); or they could contribute to the sub-
strate-binding specificity of the cyclin-CDK enzyme,
possibly by forming part of the substrate-binding cleft. As
the structure solved by Jeffrey et al. [2] did not include a
substrate, it is difficult to evaluate the latter possibility
which remains an interesting question for the future.
The cyclin family shows high amino-acid sequence
diversity [46], and it has been surprising to find func-
tional overlap between (for example) CLN1 and CLN3
in budding yeast, which are only about 25% identical
within their most conserved region (the 'cyclin box')
[7,47,48]. The structure of the cyclin A-CDK2 complex
provides some explanation for this. Firstly, the cyclin box
defined by sequence homology defines the bulk of the
interface between cyclin A and CDK2. Secondly, the
only two completely conserved amino acids in cyclins,
Glu295 and Lys266, are shown to be involved in a critical
interaction between cyclin and the 'PSTAIRE' helix
containing one of the catalytic residues of CDK2; the
interaction is probably required to bring this catalytic
residue to the active site [2]. Thirdly, the structure shows
that cyclin A contains a structural duplication of the
cyclin box, in the form of a region which is folded in an
identical manner to the cyclin box but does not interact
with CDK2. There is only 12% amino-acid sequence
homology between the two regions making these 'cyclin
folds'. This level of homology makes even the CLN1/
CLN3 comparison [48] look pretty good.
The similar folds found between the two regions of
cyclin A having only limited sequence homology implies
that there could be proteins with the cyclin fold that will
not be recognizable by sequence inspection. Fortunately,
'threading' analysis, described by Brown et al. [1],
provides a good way to recognize this cyclin fold even
when the sequence divergence is such that homology is
not directly recognizable. For example p25, that activates
CDK5 [49,50], was considered to have little or no cyclin
homology, despite the strong functional similarity
between activation of CDK5 by p2 5 and activation of
other CDKs by cyclins. Now, threading analysis strongly
suggests that p2 5 contains a cyclin fold [1]. A number of
other proteins [1], including TFIIB, had been predicted
to be structurally similar to cyclins on the basis of
sequence comparison results [51], and threading analysis
has supported this prediction [1]. Recently, the presence
of the cyclin fold in TFIIB has been confirmed by direct
structural analysis [52].
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